---
title: "Radiopharm Theranostics calls extraordinary shareholder meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293745763.md"
description: "Radiopharm Theranostics will hold an extraordinary general meeting in Australia on Sept. 11, 2026. Shareholders will vote on approvals for the company’s capital raising package, including securities issuances under the Australian placement and a share purchase plan. Resolutions also cover issuing options to participants with an exercise price of A$0.018 expiring July 31, 2029."
datetime: "2026-07-24T11:01:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293745763.md)
  - [en](https://longbridge.com/en/news/293745763.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293745763.md)
generator: "portal-rs"
---

# Radiopharm Theranostics calls extraordinary shareholder meeting

-   Radiopharm Theranostics will hold an extraordinary general meeting in Australia on Sept. 11, 2026. \* Shareholders will vote on approvals tied to the company’s capital raising package, including securities issuances under the Australian placement. \* The meeting will also consider approval for the share purchase plan. \* Resolutions also cover the issue of options to placement and SPP participants, with an exercise price of A$ 0.018 and expiry on July 31, 2029. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-081114), on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RADX.US](https://longbridge.com/en/quote/RADX.US.md)

## Related News & Research

- [Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agent](https://longbridge.com/en/news/296102289.md)
- [Radiopharm teams up with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial](https://longbridge.com/en/news/296098148.md)
- [Profusa announces special shareholder meeting](https://longbridge.com/en/news/296272150.md)
- [Valion Bio amends 8-K to report final vote tally on reverse stock split approval](https://longbridge.com/en/news/296531983.md)
- [Tempest Therapeutics special meeting adjourned after proposal fell short of required votes](https://longbridge.com/en/news/296266762.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**